Market capitalization | $225.24m |
Enterprise Value | $175.72m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.17 |
P/S ratio (TTM) P/S ratio | 5.35 |
P/B ratio (TTM) P/B ratio | 3.40 |
Sales growth (TTM) Sales growth | 59.59% |
Turnover (TTM) Turnover | $42.09m |
As a free StocksGuide basic user, you can view the scores for all 6,951 shares worldwide.
6 Analysts have issued a CVRx Inc forecast:
6 Analysts have issued a CVRx Inc forecast:
Mar '24 |
+/-
%
|
||
Turnover | 42 42 |
60%
60%
|
|
Gross income | 35 35 |
71%
71%
|
|
EBITDA | -53 -53 |
19%
19%
|
EBIT (operating result) EBIT | -53 -53 |
19%
19%
|
Net profit | -52 -52 |
21%
21%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. It has developed the second generation Barostim neo, an implantable system designed to treat heart failure and hypertension. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2000 and is headquartered in Minneapolis, MN.
Head office | United States |
CEO | Kevin Hykes |
Employees | 200 |
Founded | 2001 |
Website | www.cvrx.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.